A study in The BMJ demonstrates that estimates of major bleeding risk in patients taking anticoagulants in clinical trials are unlikely to reflect the reality of clinical practice. Researcher Shirley ...

MADRID, Spain—A tailored treatment strategy based on the ABC-AF stroke and bleeding risk scores is no better than usual care for patients with atrial fibrillation (AF) and a low-to-moderate risk of ...

Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial. The trial had been stopped early because of a surprisingly large reduction in bleeds ...

Madrid, Spain – 30 August 2025: An individually tailored multidimensional risk-based treatment strategy was not associated with improvements in clinical outcomes compared with usual guideline-based ...

Abelacimab shows promise in reducing bleeding risks compared to rivaroxaban, offering a safer anticoagulation option for atrial fibrillation patients. Factor XI inhibition could optimize ...

Select high bleeding risk (HBR) patients can safely receive just 1 or 3 months of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) without more ischemic events, ...

DEAR DR. ROACH: I am a 70-year old woman with a prior history of asymptomatic atrial fibrillation (AFib). I’ve been in normal sinus rhythm since having two catheter ablations in 2018. I take Eliquis ...

In patients with AF, abelacimab, compared with rivaroxaban, is associated with decreased bleeding across multiple bleeding risk categories. Abelacimab is associated with reduced bleeding compared with ...

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...

Venous thromboembolism (VTE) remains a significant cause of morbidity and mortality among hospitalised medical patients. Ongoing efforts to refine risk assessment and optimise prophylactic strategies ...